TCGA-IQ-A6SG-01A-12R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.400
- MYC_TARGETS_V1+0.390
- MTORC1_SIGNALING+0.290
- E2F_TARGETS+0.250
- G2M_CHECKPOINT+0.220
- GLYCOLYSIS+0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
- DNA_REPAIR+0.190
- ADIPOGENESIS+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- INTERFERON_GAMMA_RESPONSE-0.550
- ALLOGRAFT_REJECTION-0.470
- MYOGENESIS-0.300
- COMPLEMENT-0.270
- APICAL_SURFACE-0.260
- ANDROGEN_RESPONSE-0.240
- INFLAMMATORY_RESPONSE-0.210
- KRAS_SIGNALING_UP-0.210
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-NK-A5CR-01A-11R-A26W-07 | — | cohortSQ2 | 0.845 |
| 2 | e235012b-4b29-478a-abad-6a70cd949cfa | — | — | 0.836 |
| 3 | MNG332 | — | — | 0.829 |
| 4 | MNG1055 | — | — | 0.817 |
| 5 | MNG1011 | — | — | 0.815 |
| 6 | TCGA-2F-A9KP-01A-11R-A38B-07 | — | — | 0.812 |
| 7 | TCGA-60-2722-01A-01R-0851-07 | — | cohortSQ2 | 0.809 |
| 8 | SAMN03290931 | — | — | 0.809 |
| 9 | TCGA-77-6845-01A-11R-1949-07 | — | cohortSQ2 | 0.809 |
| 10 | TCGA-21-1075-01A-01R-0692-07 | — | cohortSQ2 | 0.808 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.220 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.110 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.050 | Inavolisib | — uncovered |